CVI Holdings’s Moleculin Biotech MBRX Stock Holding History

CVI Holdings’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-161	Closed	-$294K	–	70
2019 Q1	$294K	Buy	+161	New	+$480K	0.28%	28

Other funds holding MBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

WIC

Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

CVI Holdings's MBRX Position: Q2 2019 in Review

CVI Holdings sold out of Moleculin Biotech (MBRX) in Q2 2019, closing a stake of 161 shares — an estimated $294K sold.

CVI Holdings first reported a position in MBRX in Q1 2019 and held it in 1 quarter. The position peaked at $294K in Q1 2019. 19 funds tracked by Wall St. Rank hold MBRX as of Q2 2019.

CVI Holdings reported no remaining Moleculin Biotech position as of Q2 2019 after selling out during the quarter.
CVI Holdings sold 161 Moleculin Biotech shares in Q2 2019, an estimated $294K.
CVI Holdings first reported a position in Moleculin Biotech in Q1 2019 and held it in 1 quarter.
CVI Holdings's Moleculin Biotech position peaked at $294K in Q1 2019.
19 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2019.

Based on CVI Holdings's 13F filing for Q2 2019, filed 14 Aug 2019.